Ipsen, Interprotein in endocrine disease deal

Ipsen Group (Euronext:IPN; Pink:IPSEY) and Interprotein Corp. (Osaka, Japan) partnered to develop therapeutic peptides to treat endocrine diseases including Cushing's disease. Ipsen will have an exclusive option to license candidates developed during the partnership.

Interprotein is eligible for EUR 165 million ($177.2 million) in milestones, plus royalties. The partners did not disclose candidates or targets in the deal and did not respond to inquiries. ...